Abstract:CONSPECTUS: Human immunodeficiency virus (HIV) reverse transcriptase (RT) contains two distinct functional domains: a DNA polymerase (pol) domain and a ribonuclease H (RNase H) domain, both of which are required for viral genome replication. Over the last 3 decades, RT has been at the forefront of HIV drug discovery efforts with numerous nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) approved by the FDA. However, all these RT inhibitors target only the pol function, and inhibitors of RT-associated RNase H have yet to enter the development pipeline, which in itself manifests both the opportunity and challenges of targeting RNase H: if developed, RT RNase H inhibitors would represent a mechanistically novel class of HIV drugs that can be particularly valuable in treating HIV strains resistant to current drugs. The challenges include (1) the difficulty in selectively targeting RT RNase H over RT pol due to their close interplay both spatially and temporally and over HIV-1 integrase strand transfer (INST) activity because of their active site similarities; (2) to a larger extent, the inability of active site inhibitors to confer significant antiviral effect, presumably due to a steep substrate barrier by which the pre-existing substrate prevents access of small molecules to the active site. As a result, previously reported RT RNase H inhibitors typically lacked target specificity and significant antiviral potency. Achieving meaningful antiviral activity via active site targeting likely entails selective and ultrapotent RNase H inhibition to allow small molecules to cut into the dominance of substrates. Based on a pharmacophore model informed by prior work, we designed and redesigned a few metal-chelating chemotypes, such as 2-hydroxyisoquinolinedione (HID), hydroxypyridonecarboxylic acid (HPCA), 3-hydroxypyrimidine-2,4-dione (HPD), and N-hydroxythienopyrimidine-2,4-dione (HTPD). Analogues of these chemotypes generally exhibited improved potency and selectivity inhibiting RT RNase H over the best previous compounds and further validated the pharmacophore model. Extended structure-activity relationship (SAR) on the HPD inhibitor type by mainly altering the linkage generated a few subtypes showing exceptional potency (single-digit nanomolar) and excellent selectivity over the inhibition of RT pol and INST. In parallel, a structure-based approach also allowed us to design a unique double-winged HPD subtype to potently and selectively inhibit RT RNase H and effectively compete against the RNA/DNA substrate. Significantly, all potent HPD subtypes consistently inhibited HIV-1 in the cell culture, suggesting that carefully designed active site RNase H inhibitors with ultrapotency could partially overcome the barrier to antiviral phenotype. Overall, in addition to identifying our own inhibitor types, our medicinal chemistry efforts demonstrated the value of pharmacophore and structure-based approaches in designing active side-directed RNase H inhibitors and could provide a viable path to validating RNase H as a novel antiviral target.

In Vitro Selection of G-Rich Rna Aptamers That Target Hiv-1 Integrase

In Silico Selection of Gp120 ssDNA Aptamer to HIV-1

Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells

Inhibition of hepatitis C virus serine protease in living cells by RNA aptamers detected using fluorescent protein substrates

Screening and identification of inhibitors on HIV-1 integrase

Structure-Guided Antiviral Peptides Identification Targeting the HIV-1 Integrase

An Interlocked Dimeric Parallel-Stranded DNA Quadruplex: A Potent Inhibitor of HIV-1 Integrase

Selection of Rna Aptamers That Bind Specifically to the Ns3 Protease of Hepatitis C Virus

Symmetrical 1-Pyrrolidineacetamide Showing Anti-Hiv Activity Through a New Binding Site on HIV-1 Integrase.

High-throughput sequence analysis reveals structural diversity and improved potency among RNA inhibitors of HIV reverse transcriptase

Design, Synthesis and Biological Evaluation of Thiazolo[3, 2-A]pyrimidine Derivatives As Novel RNase H Inhibitors

Identifying and Characterizing a Functional HIV-1 Reverse Transcriptase-binding Site on Integrase

Identification of a Novel HIV‐1 Integrase Strand Transfer Inhibitor: A Synergistic Approach Combining Pharmacophore Modelling and In Vitro Assays

Potent Inhibition of Human Influenza H5n1 Virus by Oligonucleotides Derived by Selex

A Dna Aptamer Against Influenza A Virus: an Effective Inhibitor to the Hemagglutinin-Glycan Interactions

Cutting into the Substrate Dominance: Pharmacophore and Structure-Based Approaches Toward Inhibiting Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H

Discovery of Inhibitors to Block Interactions of HIV-1 Integrase with Human LEDGF/p75 Via Structure-Based Virtual Screening and Bioassays.

Molecular mechanism of HIV-1 integrase-vDNA interactions and strand transfer inhibitor action: a molecular modeling perspective.

Screening of Highly Effective Sirna Sequence Targeting to HIV-1 Vif and the Lentiviral-mediated Antiviral Research in Vitro

Progress in Research on HIV-1 Integrase and Its Inhibitors

3D-QSAR Modeling, Surflex Docking and Reverse Docking Studies of Diketo-Acid Derivatives as Potent Integrase/Rnase H Inhibitors